en

PRODUCT DETAIL

Bavencio 20 mg/ml infúzny koncentrát

Code 5581C
MA number EU/1/17/1214/001
Product Form: con inf 1x10 ml/200 mg (liek.inj.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
MAH, country: Merck Europe B.V., Netherland
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
L01FF04 Avelumab
Shelf life: 36
Container: glass vial
Route of admin.: Intravenous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 19.08.2020
SmPC + PL: European Medicines Agency's database
Dokument: Bavencio_Karta pacienta.pdf  
Dokument: Bavencio_Prirucka pre zdravotnickych pracovnikov.pdf  
Dokument: Bavencio_Prirucka pre pacientov.pdf  
Safety feature Yes
Data update: 23.03.2025
eu-flag.png sk-flag.png